Treatment of Granulomas in Patients With Ataxia Telangiectasia
Authors:
Open Access
- 18 September 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2000
Abstract
Background: Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia, growth retardation, immunodeficiency, chronic pulmonary disease and chromosomal instability. Cutaneous granulomas are a known phenomenon in A-T but extra-dermal manifestation of granulomas at bone and synovia has not been reported so far. The clinical presentation, immunological findings, the long-term course and treatment options of eight patients with severe granulomas will be reported. Methods: From our cohort of 44 classical A-T patients, eight patients aged 2–11 years (18.2%) presented with granulomas. Immunological features of patients with and without granulomas were compared. Five patients suffered from cutaneous manifestation, in two patients we detected a bone and in one a joint involvement. Patients with significant extra-dermal involvement as well as one patient with massive skin manifestation were treated with TNF inhibitors. The patient with granulomas at his finger joint and elbow was treated with hematopoietic stem cell transplantation (HSCT). Results: Interestingly, seven of eight patients with granulomas were total IgA deficient, but there were no differences in IgG and IgM levels. All lymphocytes subsets were equally distributed except patients with granuloma had significantly lower naïve CD8 cells. In patients without treatment, four of eight showed a slow but significant enlargement of the granuloma. Treatment success with TNF inhibitors was variable. In one patient, treatment with TNF inhibitors led to a total remission for 3 years up to now. In two patients, treatment with TNF inhibitors led to a partial regression of granulomas. Treatment interruptions caused deterioration again. Conclusions: Granulomas in A-T progress slowly over years and can lead to significant morbidity.Treatment with TNF inhibitors was safe and in part successful in our patients. Interestingly HSCT leads to complete remission, and indicates that aberrant immune function is responsible for granulomas in A-T patients. What This Study Adds to the Field: Granulomas in A-T progress slowly over years and can lead to significant morbidity. Treatment with TNF inhibitors was safe and in part successful in our patients. AT A GLANCE COMMENTARY: Scientific knowledge on the subject: Little is known about the clinical presentation, course and treatment of granulomas in ataxia telangiectasia (A-T). In addition, this is the first report of extra-dermal manifestation of granulomas at bone and synovia in patients with A-T. What This Study Adds to the Field: Granulomas in A-T progress slowly over years and can lead to significant morbidity. Treatment with TNF inhibitors was safe and in part successful in our patients.Keywords
This publication has 48 references indexed in Scilit:
- A comprehensive review and update on Crohn's diseaseDisease-a-Month, 2018
- Ataxia-telangiectasia: Immunodeficiency and survivalClinical Immunology, 2017
- DNA Damage Signaling Instructs Polyploid Macrophage Fate in GranulomasCell, 2016
- Foreign Body GranulomasDermatologic Clinics, 2015
- Infliximab for Treatment of Granulomatous Disease in Patients with Common Variable ImmunodeficiencyJournal of Clinical Immunology, 2014
- Infections of the respiratory system in patients with ataxia-telangiectasiaPediatric Pulmonology, 2013
- Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: A genotype-phenotype studyHuman Mutation, 2011
- CD8+ T Cells: Foot Soldiers of the Immune SystemImmunity, 2011
- Potential target of infliximab in autoimmune and inflammatory diseasesAutoimmunity Reviews, 2007
- Granulomatous disease in common variable immunodeficiencyCurrent Allergy and Asthma Reports, 2005